AEM vs RGLD

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

RGLD presents a dichotomy between a rock-solid balance sheet and an extreme valuation premium. The Piotroski F-Score of 4/9 indicates stable financial health, supported by a very low Debt/Equity ratio (0.13) and strong liquidity. However, the current price of $268.12 trades at a massive premium to both the Graham Number ($113.0) and the Intrinsic Value ($46.9). While revenue growth is explosive (86.1%), the negative earnings growth (-28.9%) and recent string of earnings misses suggest the current valuation is speculative and disconnected from fundamental growth.